Overview

Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology

Status:
Unknown status
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Chronic allograft nephropathy is one of dominant causes of long term kidney transplant failure. Its main histological determinant is interstitial fibrosis and tubular atrophy. Mechanisms of these changes are multifactorial and are not completely elucidated. Epithelial mesenchymal transition (EMT) might be one of the mechanisms. On molecular level role of renin angiotensin aldosterone system (RAAS) has been recognized. Recently, mineralocorticoid hormone aldosterone has been proposed as a possible direct contributor to the progression of renal injury and fibrosis, beside his well known role as a regulator of extracellular fluid volume and sodium and potassium balance. In this study the investigators will determine the impact of mineralocorticoid receptor antagonist use on progression of chronic scores in transplanted kidney over one year. The investigators hypothesis is that spironolactone use in kidney transplant patients will slow down progression of chronic histological changes- interstitial fibrosis, tubular atrophy and arteriolar hyalinosis.
Phase:
Phase 4
Details
Lead Sponsor:
Clinical Hospital Merkur
Treatments:
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Spironolactone